Phosphatase and tensin homolog protein (PTEN)

Phosphatase and tensin homolog protein (PTEN) is a dual-specificity phosphatase with both lipid and protein phosphatase activity, primarily acting as a tumor suppressor by dephosphorylating phosphatidylinositol (3,4,5)-trisphosphate (PIP3) to PIP2, thereby antagonizing PI3K/AKT signaling and inhibiting cell proliferation, survival, and growth[1][3][5][7][9]. Structurally, PTEN is a 403-amino acid protein with defined phosphatase and C2 domains that mediate catalysis and membrane association, respectively[5][6]. PTEN regulates numerous biological processes such as cell cycle progression, migration, apoptosis, and maintenance of genomic stability. Germline or somatic mutations in PTEN lead to a wide range of cancers and hamartoma syndromes. PTEN loss or mutation is also a key biomarker and determinant of therapeutic response to inhibitors of the PI3K/AKT/mTOR pathway[1][7][9]. Despite intense research, PTEN itself remains a difficult direct drug target, but its status is crucial for guiding therapy and prognosis in oncology.

Other names

PTENPhosphatase and tensin homolog deleted on chromosome 10Mutated in multiple advanced cancers 1 (MMAC1)Phosphatase and tensin homologuePTEN tumor suppressor

Drugs targeting the PI3K/AKT/mTOR pathway can be more effective in cells or tumor types with intact PTEN function, or conversely, loss of PTEN can confer resistance or sensitivity to pathway inhibitors[1][10]. Restoration of PTEN function or mimicking its phosphatase activity is under investigation therapeutically.